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Desensitization of the
Pulmonary Adenylyl Cyclase System
A Cause of Airway Hyperresponsiveness in Congestive Heart Failure?
Mathias M. Borst, MD, Wilke Beuthien, MD, Carsten Schwencke, MD, Paul LaRose´e, MD,
Rainer Marquetant, PHD, Markus Haass, MD, Wolfgang Ku¨bler, MD, Ruth H. Strasser, MD
Heidelberg, Germany
OBJECTIVES This study was designed to investigate whether the adrenergic signal transduction in the lung
and the responsiveness of airway smooth muscle to adrenergic stimulation are modulated in
congestive heart failure.
BACKGROUND Wheezing and airway hyperresponsiveness are often present in heart failure. In the failing
heart, chronic adrenergic stimulation down-regulates beta-adrenergic receptors and adenylyl
cyclase. We hypothesized that airway dysfunction in heart failure could be due to a similar
modulation of pulmonary adrenergic signal transduction.
METHODS Heart failure was induced in rats by aortic banding, resulting in increases in plasma
norepinephrine, lung wet weight indicating congestion and left ventricular end diastolic
pressure after four weeks. Beta-receptor densities in pulmonary plasma membranes were
measured by radioligand binding using [125I]iodocyanopindolol. The G protein levels were
determined by Western blot. Adenylyl cyclase activities in lung membranes were quantified
as [32P]cAMP (cyclic adenosine-59-monophosphate) synthesis rate. To functionally assess
airway smooth muscle relaxation, carbachol-precontracted isolated tracheal strips were used.
RESULTS Beta-receptor density was significantly decreased in heart failure from 771 6 89 to 539 6
44 fmol/mg protein without changes in receptor affinities. The beta1-/beta2-subtype ratio,
however, remained constant. The Gia and Gsa protein expression was unchanged. Adenylyl
cyclase activity stimulated directly with forskolin was decreased by 28%. Relaxation of tracheal
strips in response to isoproterenol and forskolin, but not to papaverin, was diminished by
30%.
CONCLUSIONS In heart failure, the down-regulation of pulmonary beta-receptors and concomitant decrease
in adenylyl cyclase activity result in a significant attenuation of cAMP-mediated airway
relaxation. These mechanisms may play a pivotal role in the pathogenesis of “cardiac asthma.”
(J Am Coll Cardiol 1999;34:848–56) © 1999 by the American College of Cardiology
Dyspnea is one of the most distressing symptoms of
congestive heart failure (CHF). Its clinical features often
resemble asthma attacks, having led to the term “cardiac
asthma” originally coined by Hope in 1835 (1). Since then,
airway obstruction has been observed to occur in heart
failure both clinically and experimentally (2). Airway func-
tion in CHF has been thoroughly studied in the past (2),
and there is accumulating clinical evidence that one crucial
component of bronchial narrowing in CHF is hyperrespon-
siveness to cholinergic stimuli with subsequent constriction
of airway smooth muscles (3–7).
Various mechanisms have been proposed to be involved
in the airway hyperresponsiveness associated with CHF,
including constriction by vagal reflexes, unspecific bronchial
C-fiber activation, thickening of bronchial walls, changes in
epithelial sodium and water transport and increased endo-
thelin levels (2,8). The potential role of alterations in the
adenylyl cyclase (AC)-dependent signal transduction system
of the respiratory tract, however, has seldom been taken into
consideration. This pathway, which is pivotal for the regu-
lation of airway smooth muscle tone, is known to be
extensively regulated in the failing myocardium.
Heart failure is associated with an early and progressive
sympathetic nervous hyperactivity (9), resulting in down-
regulation of myocardial beta-adrenergic receptors and a
decrease in their mRNA levels (10–13). It has long been
known that the beta-receptor-mediated inotropic responses
of the heart are attenuated in CHF (14). Beyond the level of
adrenergic receptors, CHF results in an increased expression
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of cardiac inhibitory G proteins (15,16) and a selective
reduction in the mRNA levels of the myocardial AC
isoform type V (17), a finding associated with a diminution
of receptor-independent cardiac AC activity (17). These
changes have been characterized for the cardiac signal
transduction system pathway, but respective changes in the
respiratory tract have not been investigated. It is conceivable
that in CHF, an imbalance in the AC signal transduction
system of airway smooth muscles paralleling the changes
occurring in the myocardium might ensue a reduction in the
bronchial relaxation mediated by beta-receptors and, as a
consequence, a sensitization to constrictive stimuli.
A rapid desensitization and uncoupling of beta-
adrenergic receptors in lungs from rats treated with cat-
echolamines was described previously (18,19). More re-
cently, chronic administration of catecholamines has been
found to induce down-regulation and functional uncoupling
of pulmonary beta-receptors, a finding associated with
diminished airway relaxant responses to adrenergic agonists
(20,21) and with reduced pulmonary mRNA levels for
beta2-adrenergic receptors (21,22). In obstructive lung dis-
eases, chronic administration of beta-adrenergic drugs is
known to cause homologous desensitization of beta-
adrenergic receptors, a finding associated with increased
bronchial responsiveness to cholinergic challenge in asth-
matics (23). These data support the hypothesis that in CHF
the AC signal transduction system in respiratory tissue
might play a pivotal role in the development of bronchial
hyperresponsiveness. However, this issue has not been
clarified thus far.
In the present study, the regulatory mechanisms of the
pulmonary AC signal transduction system and the subse-
quent functional changes in airway smooth muscle respon-
siveness were investigated in a rat model of CHF induced by
aortic banding.
METHODS
Reagents. Thiopental-Na1 was purchased from BYK-
Gulden (Konstanz, Germany), ketamine-HCl was from
Parke-Davis (Berlin, Germany) and diazepam was from
Hoffmann-La Roche (Grenzach-Wyhlen, Germany). Al-
prenolol, benzamidine, bovine serum albumin, carbachol
(carbamylcholine chloride), forskolin, GTP, Gpp(NH)p,
isobutylmethylxanthine, (2)-isoproterenol-(1)-bitartrate,
papaverin, phenylmethylsulfonylfluoride and Tween-20
were purchased from Sigma (Munich, Germany). The ICI
118,551 was from Tocris/Biotrend (Cologne, Germany).
The NaF was from Aldrich (Milwaukee, Wisconsin). Di-
thiothreitol (DTT) and EGTA were obtained from Serva
(Heidelberg, Germany). Bradford reagent was bought from
Biorad (Munich, Germany). Cyclic adenosine-59-
monophosphate (cAMP), creatine, phosphocreatine and
creatine kinase were purchased from Boehringer (Mann-
heim, Germany). Both [125I]iodocyanopindolol and
[a-32P]ATP were from NEN (Dreieich, Germany). The
ECL chemoluminescence Western blotting detection re-
agent was bought from Amersham (Little Chalfont, UK).
All other chemicals were of analytical grade and were
obtained from Merck (Darmstadt, Germany).
Animal experiments. Male Wistar rats (90 g) obtained
from Thomae (Biberach/Riss, Germany) were anesthetized
by intraperitoneal injection of ketamine (50 mg/kg body
weight) and diazepam (5 mg/kg) and ventilated with oxy-
gen. As described previously (24), the left hemithorax was
opened, the ascending aorta was partially occluded using
tantalum hemostatic clips with a defined internal diameter
of 0.711 mm (Edward Weck, Research Triangle Park,
North Carolina) and the wound was sutured (n 5 34).
Sham-operated animals (n 5 23) underwent the same
surgical procedure without insertion of the clip. The peri-
operative mortality ranged at ;10%.
After 3, 7 or 28 days the animals were again anesthetized
with thiopental (50 mg/kg i.p., dissolved in isotonic saline).
A femoral artery was canulated using a 2F PE 50 line, and
a 3.5-ml EDTA blood sample was taken for catecholamine
measurements. The rats were tracheotomized and mechan-
ically ventilated at ;50 cycles/min (Animal Respirator
4600, Rhema-Labortechnik, Hofheim/Ts., Germany) with
air at a peak pressure of ;15 cm of water. The thorax was
opened, and a 0.8-mm stainless steel cannula connected to
a pressure transducer was inserted through the free left
ventricular wall to record left ventricular pressures on a
polygraph (PRC 21 and MVO-0600, FMI, Seeheim/
Oberbeerbach, Germany; WeKagraph 350R, WKK, Kalt-
brunn, Switzerland). Lungs were rapidly excised, rinsed in
ice-cold isotonic saline, quickly blotted, weighed and frozen
in liquid nitrogen. Hearts were processed in the same
manner after rapid dissection of left and right ventricles.
Tissues were stored at 280°C until further analysis.
All animal experiments were performed with official
approval by the authorities of the Regierungspra¨sidium
Karlsruhe, Germany.
Membrane preparation. For the preparation of plasma
membranes, hearts or lungs were homogenized in 35-ml
buffer A containing (mmol/liter): Tris-HCl 50; EDTA 5;
EGTA 2 (pH 7.2, 4°C), using a Polytron (Kinematika,
Lucerne, Switzerland; 10,000 rpm, 3 3 10 s). The protein-
ase inhibitors benzamidine (1 mmol/liter) and phenylmeth-
Abbreviations and Acronyms
AC 5 adenylyl cyclase
ANOVA 5 analysis of variance
Bmax 5 beta-receptor density as maximal specific
binding sites
cAMP 5 cyclic adenosine-59-monophosphate
CHF 5 congestive heart failure
DTT 5 dithiothreitol
KD 5 beta-receptor dissociation constant
LVEDP 5 left ventricular end diastolic pressure
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ylsulfonylfluoride (1 mmol/liter) were used in all buffers for
lung membrane preparation. After sedimentation (350g,
10 min, 4°C) the supernatant was filtered through two layers
of cheesecloth. Plasma membranes were collected by cen-
trifugation (48,000g, 10 min, 4°C) and washed twice in
35-ml buffer A by centrifugation (48,000g, 10 min, 4°C).
The final membranes were resuspended in 50 mmol/liter
Tris-HCl (pH 7.4), to give a final protein concentration of
;2 mg/ml. Aliquots were stored at 280°C.
Radioligand binding. The density of beta-adrenergic re-
ceptors was determined by radioligand binding using the
radiolabeled beta-antagonist [125I]iodocyanopindolol (25).
For saturation isotherms the membranes were resuspended
in 50 mmol/liter Tris-HCl (pH 7.4). Increasing concen-
trations of the radioligand (10 to 320 pmol/liter) in
50 mmol/liter Tris-HCl, 2 mmol/liter EDTA, and
1 mmol/liter EGTA were incubated in duplicates (pH 7.5,
60 min, 30°C) with plasma membranes (lung: 5 to 10 mg;
heart: 15 to 30 mg). For competition binding assays the
membranes were resuspended in 75 mmol/liter Tris-HCl,
12.5 mmol/liter MgCl, and 1 mmol/liter EDTA (pH 7.4).
The radioligand [125I]iodocyanopindolol was added to give
a final concentration of 50 pmol/liter. Increasing concen-
trations of the beta-agonist isoproterenol (10 pmol/liter to
0.1 mmol/liter) were added in the absence or in the presence
of the non-hydrolyzable GTP-analogue Gpp(NH)p
(0.1 mmol/liter). To determine the ratio of adrenergic
receptor subtypes, two site competition curves using the
specific beta1- and beta2-antagonists bisoprolol and ICI
118,551 were established. The antagonists were added to
the membrane suspension in concentrations of 10 pmol/liter
to 0.1 mmol/liter. The incubation was stopped by rapid
vacuum filtration on Whatman GF/C filters. The filters
were washed (3 3 4 ml, 50 mmol/liter Tris-HCl, pH 7.5)
and counted in a g-counter (Multicrystal, Berthold, Mu-
nich, Germany) with a counting efficiency of 84%. Nonspe-
cific binding was determined as the residual binding in the
presence of 10 mmol/liter alprenolol.
Adenylyl cyclase activity. Adenylyl cyclase activity was
determined according to the method of Salomon et al. (26)
modified according to Jakobs et al. (27). Final assay con-
centrations were: [a-32P]ATP 0.5 mmol/liter (’200,000
cpm/tube), 75 mmol/liter Tris-HCl (pH 7.5), 12.5 mmol/
liter MgCl2, 1.0 mmol/liter EDTA, 0.1 mmol/liter GTP,
1.0 mmol/liter DTT, 0.1 mmol/liter cAMP, 1.0 mmol/liter
isobutylmethylxanthine, 20 mmol/liter phosphocreatine and
10 units/tube creatine kinase. To stimulate AC (2)-
isoproterenol (0.1 mmol/liter), NaF (10 mmol/liter) or
forskolin (0.1 mmol/liter) was added as indicated. The
incubation was started by the addition of plasma membranes
(lung: ;10 mg; heart: ;60 mg protein/tube) and stopped
after 10 min at 37°C by the addition of 500 ml of NaHCO3
(120 mmol/liter) and 500 ml zinc acetate (125 mmol/liter).
The radiolabeled cAMP was isolated according to the
method of Jakobs et al. (27) using aluminum oxide columns.
For quantification, Cerenkov radiation was determined with
a counting efficiency of 50%.
Immunoblot analysis of the alpha-subunit of Gi and Gs
proteins. Plasma membrane preparations were subjected to
gel electrophoresis (100 mg protein/lane) according to the
method of Laemmli et al. (28). The proteins were trans-
ferred to nitrocellulose according to Towbin et al. (29).
Rabbit polyclonal antibodies directed against the
C-terminus of the alpha-subunit of Gia1 and Gia2 proteins
and against the C-terminus of the alpha-subunit of Gsa1
and Gsa2 proteins were used as primary antibodies (30).
Immunocomplexes were visualized by the ECL system.
Densitometric analysis of the autoradiograms (X-Omat AR
5 film, Kodak, Rochester, New York) was performed with a
laser densitometer (Ultroscan, LKB Pharmacia, Freiburg,
Germany) by direct comparison of controls and lung mem-
branes derived from animals with aortic banding.
Catecholamines. Norepinephrine levels were measured in
deproteinized plasma samples by radioenzymatic assay and
electrochemical detection, as described previously (31).
Protein assay. Membrane protein concentrations were de-
termined according to the method of Bradford using bovine
serum albumin as standard (32).
Organ bath tracheal contraction experiments. For func-
tional studies, tracheae were rapidly dissected and allowed to
recover for 1 h at room temperature in a modified Krebs-
Henseleit buffer containing (mmol/liter): NaCl 116; KCl
4.7; MgSO4 1.1; KH2PO4 1.17; NaHCO3 24.9; CaCl2
2.52; glucose 8.3; pyruvate 2.0; and EDTA 0.03. The
medium was equilibrated with O2: CO2 95%: 5%. As
described by Lemoine and Overlack (33), tracheal strips,
each encompassing three to four cartilaginous rings, were
prepared and mounted in 10 ml organ baths containing
gassed Krebs-Henseleit buffer at 37°C. Rings were allowed
to relax maximally for 30 min under a tension adjusted to
10 mN. At that time, equilibrium conditions were reached.
Changes in tension during addition of pharmacologic ago-
nists were recorded under isometric conditions using a
force-displacement transducer (Grass, Quincy, Massachu-
setts), a preamplifier (Hellige, Freiburg, Germany) and a
strip chart recorder (Heath, Benton Harbor, Michigan).
Carbachol at a concentration of 1 mmol/liter (which in
preliminary experiments was found to elicit 80% of maximal
contraction) was used to precontract tracheal strips. After
15 min, no further increase in tension was observed. In
preliminary experiments, no decline in the contractile re-
sponse to carbachol had been noted, making subsequent
corrections for baseline tone unnecessary. Relaxation in
response to isoproterenol added to the organ bath at
concentrations from 10 pmol/liter to 10 mmol/liter, to
forskolin (1 mmol/liter) and to papaverin (0.1 mmol/liter)
was measured under steady-state conditions.
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Data analysis. Data reported are mean 6 SEM. Statistical
comparison of group means was performed using the
two-tailed Student t test (34). Saturation and competition
curves were established using least-square fitting based on
the mass action law (35). Concentration response curves
were obtained from multiple regression analysis with vari-
able hillslopes. Statistical comparison of the saturation and
concentration response curves was performed by analysis of
variance (two-way ANOVA).
RESULTS
Induction of heart failure and neuroendocrine activation.
Banding of the ascending aorta resulted in progressive left
ventricular hypertrophy, which became highly significant as
early as three days after the intervention (Fig. 1A). In
addition, significant right ventricular hypertrophy was
present after four weeks, reflecting an increase in pulmonary
artery pressure due to left ventricular backward failure (Fig.
1B). Left ventricular end diastolic pressure (LVEDP),
which was obtained in nine animals after four weeks,
increased from 4.6 6 1.1 to 11.1 6 1.3 mm Hg (p # 0.005)
as compared with control animals. Pulmonary wet weight
was also significantly increased after four weeks (Fig. 1C).
The increase in lung wet weight was due to pulmonary
congestion and not to an increase in cellular elements
because total membrane protein content was not different
between lungs from animals with CHF and control animals
(8.5 6 1.0 vs. 8.2 6 0.4 mg/lung). In 20% of the animals,
pleural effusions, pericardial effusions and ascites were ob-
served. As a marker of neuroendocrine activation, resting
plasma levels of norepinephrine were significantly elevated
after four weeks from 3 6 1 to 6 6 1 nmol/liter (p # 0.05).
Regulation of beta-adrenergic receptors. The density of
beta-adrenergic receptors (Bmax) in lung plasma membranes
tended to decrease during the development of CHF, and a
significant reduction by 30% was observed after four weeks
(Fig. 2). There was no change in the affinity (KD) of the
beta-adrenergic receptor for the radiolabeled antagonist
[125I]iodocyanopindolol. Similarly, the affinities of the beta-
receptor for the agonist isoproterenol remained unaltered in
CHF. Lung homogenates from rats with CHF (n 5 3) had
a high affinity binding site, with an EC50 of 10.5 nmol/liter
versus 15.0 nmol/liter in sham-operated rats (n 5 3; NS).
The low-affinity binding site had an EC50 of 46.8 mmol/
liter in CHF and of 82.7 mmol/liter in controls (NS). The
fraction of pulmonary beta-adrenergic receptors forming the
agonist-promoted high-affinity state was 55% in CHF (n 5
3) versus 52% in control animals (n 5 3). The ratio of
beta1:beta2-adrenergic receptor subtypes was 20:80 in pul-
monary membranes derived from rats with and without
CHF. Regression analysis revealed that the decrease in total
pulmonary beta-receptor density was dependent on the
severity of CHF. Bmax showed a significant negative linear
correlation to LVEDP (Fig. 3A). Similarly, Bmax correlated
negatively with lung wet weight but was remarkably con-
stant in control animals (Fig. 3B). The decrease of pulmo-
nary beta-adrenergic receptors was paralleled by similar
changes of myocardial beta-receptors. After four weeks Bmax
was 57 6 5 fmol/mg membrane protein in the failing
myocardium (n 5 14) as compared with 68 6 8 fmol/mg in
controls (n 5 8; mean 6 SEM; p # 0.001). Again, no
difference in KD values was detected (data not shown).
Regulation of G proteins. To assess whether CHF in-
duced a regulation of pulmonary G proteins, expression of
the alpha-subunits of Gi and Gs proteins was determined by
Western blot. As opposed to the regulation of beta-
adrenergic receptors, relative G protein levels were un-
changed in lung membranes from rats with CHF. When
compared with sham-operated animals, Gi protein levels
were 105 6 20%, 97 6 3% and 104 6 2% after 3, 7 and 28
days after aortic banding (n 5 3, measured in triplicates).
Similar data were obtained for Gs proteins (Fig. 4).
Regulation of AC activity. Total AC activity was deter-
mined in pulmonary membrane preparations under basal
conditions and after stimulation of the enzyme by 0.1 mmol/liter
isoproterenol, by 10 mmol/liter NaF or by 0.1 mol/liter
forskolin. At the earlier stages of myocardial hypertrophy
(i.e., after three and seven days) no differences in AC
activities were observed (data not shown). After 28 days,
however, when signs of CHF had developed, lung AC
Figure 1. Development of myocardial hypertrophy and heart failure after aortic banding. Organ wet weights are shown relative to body
weight (BW). (A) Progressive left ventricular (LV) hypertrophy occurs early after aortic banding (closed squares) as compared with
sham-operated rats (open squares). (B) Right ventricular (RV) weight increases in animals with banded aorta as left heart failure develops.
(C) Twenty-eight days after aortic banding, lung wet weight is increased significantly, indicating congestive heart failure (CHF). Mean 6
SEM. *p # 0.05; **p # 0.0005 (two-tailed t test).
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activity (n 5 6) was significantly reduced as compared with
control animals (n 5 7; Fig. 5). This was true for basal AC
activity (p 5 0.004) as well as stimulation with isoproterenol
(p 5 0.002) and forskolin (p 5 0.013). The decrease in
NaF-stimulated activity remained just below significance
(p 5 0.056).
As opposed to these alterations in lung membranes, the
decreased responsiveness of myocardial AC activity oc-
curred very early in the development of CHF. Forskolin-
stimulated enzyme activity in the heart was reduced by 39%
after 3 days (n 5 5; p 5 0.004), by 44% after 7 days (n 5
5; p 5 0.023) and by 39% after 28 days (n 5 13; p 5
0.0001). All AC assays were performed in the presence of
GTP (see Methods), because control experiments’ omission
of GTP reduced cAMP yield by ;40% without influencing
relative changes (data not shown).
Airway responsiveness to inhibition and stimulation of
the adenylyl cyclase system. Exposure of tracheal strips to
carbachol (1 mmol/liter) induced a submaximal increase in
tension (80% of the maximal tension obtained with carba-
chol at 0.3 mmol/liter). No significant difference between
both groups was seen in the response to carbachol. Devel-
oped force increased to a similar extent from 5.1 6 0.6 to
29.6 6 2.6 mN in rats 28 days after aortic banding (n 5 12)
and from 6.5 6 1.3 to 25.1 6 3.1 mN in controls (n 5 12).
The response to isoproterenol (10 pmol/liter to 10 mmol/
liter) is depicted in Figure 6. Isoproterenol reduced the
Figure 2. Radioligand binding assay for beta-adrenergic receptors in lung membrane preparations from rats with CHF after aortic banding
and from control animals was performed using [125I]iodocyanopindolol (A). Saturation isotherms established by the least-squares method
are from single data referring to CHF and control animals 28 days after aortic banding. Nonspecific binding (bottom) was determined
as the residual binding in the presence of 10 mmol/liter alprenolol. (B) Density (Bmax) and affinity (KD) of pulmonary adrenergic receptors
from rats at 3 days (n 5 6), 7 days (n 5 11) and 28 days (n 5 12) after aortic banding (hatched bars) are compared with respective controls
(n 5 5, 9 and 10, respectively) (open bars). Mean 6 SEM; *p # 0.001 (two-way ANOVA). KD values (shown in numbers) were not
significantly different. (C) Ratio of adrenergic receptor subtypes as determined by two-site competition curves obtained with the
beta1-selective receptor antagonist bisoprolol (Biso) and the beta2-selective antagonist ICI 118,551 (ICI). No differences in the
beta1-/beta2-subtype ratio of 20:80 were observed between lungs from rats with CHF (after 28 days; n 5 3) and from sham-operated
control animals (n 5 3).
Figure 3. Linear regression analysis (695% CI) of pulmonary beta-adrenergic receptor density (Bmax) and parameters of left ventricular
failure in rats with CHF 28 days after aortic banding. For comparison, sham-operated control are also shown. (A) Left ventricular end
diastolic pressure: r 5 0.62 (n 5 9; p # 0.05). (B) Lung wet weight: r 5 0.71 (n 5 12; p # 0.05).
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tension in strips from CHF rats to a minimum of 19.9 6 1.2
versus 14.7 6 2.1 mN in control animals (p , 0.05),
whereas the EC50 for isoproterenol remained unchanged.
Administration of forskolin (1 mmol/liter) in the presence
of isoproterenol (0.1 mmol/liter) further relaxed precon-
tracted tracheal strips to 13.6 6 1.2 mN in CHF rats as
compared with 9.9 6 1.3 mN in controls. The effect of
forskolin was significantly (p , 0.05) reduced in CHF,
indicating that airway smooth muscle AC activity during
direct stimulation was also attenuated (Fig. 7). In contrast,
tracheal relaxation after the addition of the direct smooth
muscle relaxant papaverin (0.1 mmol/liter) fully reversed the
effect of precontraction with carbachol, showing no differ-
ence between strips from rats with CHF (5.0 6 0.7 mN;
n 5 8) and controls (7.0 6 2.1 mN; n 5 8) (Fig. 7).
DISCUSSION
The present study indicates for the first time that the
chronic neuroendocrine activation in CHF may contribute
to changes in airway function by means of a regulation of
the pulmonary AC signal transduction cascade with a
reduction of beta-adrenergic receptors and of AC activity.
Pulmonary beta-adrenergic receptors in CHF. Four
weeks after aortic banding in the rat, increases in LVEDP,
in pulmonary wet weight suggesting pulmonary congestion
and in plasma norepinephrine levels indicated frank CHF.
Concomitantly, the density of pulmonary beta-adrenergic
receptors is decreased. The extent of this receptor down-
regulation in individual animals is significantly correlated to
the degree of left ventricular dysfunction.
For the failing myocardium, it is well known that beta-
adrenergic receptors are down-regulated (10–13), resulting
in a blunted inotropic response of the heart to adrenergic
stimuli (14). The present data demonstrate that a similar
regulation process may occur concomitantly in CHF in a
noncardiovascular organ system (i.e., the lung). The de-
crease in pulmonary beta-receptor density is similar to that
observed during pharmacologic stimulation using beta-
adrenergic agonists (20–22). In this study, changes in
receptor density could not be attributed directly to specific
cell types, but there is evidence that in CHF, beta-receptors
are significantly down-regulated in airway smooth muscle
cells, resulting in marked changes in airway function. The
experiments performed on tracheal strips showed an ;30%
decrease in maximal relaxant response of airway smooth
muscle to the beta-adrenergic agonist isoproterenol, com-
parable to effects observed after desensitization with high
doses of isoproterenol (20) or norepinephrine (21).
Autoradiographic studies have shown unanimously that
in most species (including humans), beta2-receptors and
beta2-receptor mRNA prevail in most pulmonary cell pop-
ulations, including airway smooth muscle (20,36). The ratio
of beta1:beta2-receptor subtypes of 20:80 in pulmonary
membranes was not affected by the development of CHF,
similar to findings after high-dose catecholamine treatment
(21,22). Therefore, the functional and biochemical data of
the present investigation give evidence that pulmonary
beta2-adrenergic receptors are down-regulated in CHF.
This finding is opposite to the concept of selective down-
regulation of beta1-receptors, which had been observed in the
failing ventricle (10) and has remained controversial (11).
However, as shown recently both by radioligand binding
assay and by determination of subtype-specific mRNA
levels, a down-regulation of myocardial beta2-receptors in
the failing myocardium cannot be easily demonstrated (12)
Figure 4. Absence of regulation of Gsa and Gia proteins in
pulmonary membrane preparations from rats with CHF (hatched
bars) and controls (open bars) (n 5 3). The G protein subunits
were detected by specific antibodies and visualized by a chemolu-
minescence technique (see Methods). Values derived from the
densitometric analysis (AUC, area under the curve) are shown as
percent of controls. Insets depict respective lanes from represen-
tative experiments running at 40 kDa.
Figure 5. Adenylyl cyclase activity in rat pulmonary membrane
preparations was determined in lungs from animals with CHF 28
days after aortic banding (n 5 7; hatched bars) and sham-operated
controls (n 5 7; open bars). Enzyme activity was measured under
basal conditions and during stimulation with isoproterenol (Iso,
0.1 mmol/liter), sodium fluoride (NaF, 10 mmol/liter) or forskolin
(Fors, 0.1 mmol/liter). Total lung membrane protein concentra-
tion was unchanged after aortic banding (see Results section).
Mean 6 SEM. *p # 0.05 (two-tailed t test).
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and may be missed owing to relatively low abundance of
that receptor subtype in the myocardium. Therefore, the
present data clearly show that beta2-adrenergic receptors,
not only the beta1-receptor subtype, may be regulated in
CHF.
Analysis of pulmonary beta-receptor binding characteris-
tics revealed that the KD of the radiolabeled beta-receptor
antagonist [125I]iodocyanopindolol was not altered in CHF,
which is in accordance with data obtained after chronic
catecholamine treatment (21). On the functional level, the
EC50 or the slopes of dose-response curves to isoproterenol
were not altered in CHF, supporting the notion that the
affinity of the remaining pulmonary beta-receptor popula-
tion for the beta-agonist isoproterenol was unchanged.
Because chronic sympathetic stimulation during CHF did
not change the affinities and the fraction of high-affinity
binding sites to the adrenergic agonist isoproterenol, the
rapid uncoupling of beta-adrenergic receptors observed after
short-term adrenergic stimulation (18,19) appears to be of
minor importance as compared with changes in receptor
density. However, the possibility that an initial uncoupling
of the receptor before down-regulation takes place in the
early phase of receptor regulation in CHF cannot be ruled
out.
Muscarinic receptor densities were not studied in the
present investigation. Although a sensitization to musca-
rinic agonists has been observed in patients after long-term
treatment with a highly selective beta2-adrenergic receptor
agonist (23), there are no data available suggesting any
regulation of muscarinic M2 or M3 receptors in the lung
during CHF. In the present study, no sensitization of airway
smooth muscle toward the muscarinic agonist carbachol
could be demonstrated on a functional level.
Pulmonary G protein levels in CHF. No change in the
expression of the alpha-subunit of stimulatory and inhibi-
tory G proteins (Gsa, Gia) in the lung was detected by
Western blot analysis. This finding contrasts with the
increased Gi protein and mRNA levels in the failing
myocardium (15,16). However, little is known about the
regulation of pulmonary G protein expression and function
during adrenergic stimulation (37). Therefore, the role of
the apparent differences in myocardial and pulmonary reg-
ulation of G proteins during CHF remains uncertain.
Pulmonary AC activity in CHF. In addition to the
desensitization of pulmonary beta-adrenergic receptors, the
present investigation shows a marked reduction of total
pulmonary AC activity in CHF. The reduction of the
enzyme activity in CHF is not confined to receptor-
mediated stimulation; it is also observed in the basal state
and after direct stimulation of the enzyme using the diter-
pene forskolin. Hence, these data indicate that chronic
neuroendocrine stimulation in CHF also induces a regula-
tion of the pulmonary AC at the postreceptor level.
In the myocardium, a similar reduction of forskolin-
stimulated AC activity is observed (17), although this occurs
earlier, during the development of “compensated” hypertro-
Figure 6. Concentration response curves obtained with isoproterenol (10 pmol/liter to 10 mmol/liter) in tracheal strips from rats with CHF
(n 5 8) and control animals (n 5 8). Tracheal strips were precontracted with carbachol (1 mmol/liter). Relaxant responses are plotted as
a percentage of the maximal relaxation achieved with isoproterenol (A; NS) and of the maximal relaxation obtained with papaverin (B;
p # 0.0001 by two-way ANOVA). Curves were fitted using the least-squares method. Data points are mean 6 SEM.
Figure 7. Cumulative relaxation of tracheal strips obtained with
isoproterenol (Iso, 10 mmol/liter, n 5 12), forskolin (Fors,
1 mmol/liter; n 5 12) and papaverin (Pap, 0.1 mmol/liter; n 5 8)
successively added to the organ bath after precontraction with
carbachol (1 mmol/liter). Values are plotted as percentage of
maximal contraction obtained with carbachol. Mean 6 SEM.
*p # 0.05 (two-tailed t test).
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phy. The differential time-course of AC activity in pulmo-
nary and myocardial tissue during the development of CHF
may be due to systemic overflow of norepinephrine during
“decompensation,” thus becoming only operative in the lung
at this later stage.
In the lung, little is known about the regulation of AC
during adrenergic stimulation. Therefore, the marked de-
crease in receptor-independent enzyme activity described in
this study illustrates for the first time that the pulmonary
AC isoforms are subject to pathophysiologic regulation
processes comparable with the heart. This indicates that
CHF may induce postreceptor changes in the adrenergic
signal transduction system extending to other organ systems
in a generalized fashion. The functional importance of this
pathophysiologic regulation in CHF is underlined by the
significantly diminished relaxation of tracheal strips in
response to forskolin.
In the past, forskolin has been found to be a relatively
weak relaxant of airway smooth muscle in guinea pigs (38).
In contrast, the present data indicate that direct stimulation
of airway AC with forskolin is quite effective. In control
animals, the maximal relaxation of carbachol-precontracted
tracheal strips achieved with 10 mmol/liter isoproterenol
could be augmented by 57% when forskolin was added.
Because this effect was even greater in CHF (106%), it may
be concluded that, in CHF, the functional antagonism
mediated by beta-receptors is diminished to a greater extent
than that due to direct activation of AC. This appears
conceivable because airway beta-adrenergic receptors may
mediate adrenergic stimuli not only by activation of AC but
also through various cAMP-independent mechanisms such
as opening of membrane KCa and maxi-K channels (37).
Finally, the changes in airway function observed in CHF
were not due to intrinsic changes in smooth muscle func-
tion, because the maximal relaxant effect of papaverin,
bypassing the adrenergic signal transduction cascade, was
found unchanged in CHF. This finding indicates that, in
CHF, the regulation of the AC system in airway smooth
muscle occurs without changes beyond the signal transduc-
tion system.
In summary, the data of this study provide experimental
evidence that the desensitization of beta-adrenergic recep-
tors and of the AC in CHF is not confined to the heart, but
that the lung is a second functionally important target organ
for these neuroendocrine regulation processes. They involve
both beta2- and beta1-receptor suptypes. Clinically, these
newly described mechanisms of impaired pulmonary signal
transduction may contribute to the bronchial hyperrespon-
siveness and to airway narrowing in patients with heart
failure—that is, the syndrome of “cardiac asthma.”
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